To further investigate the suboptimal activation of SARS-CoV-2−specific CD8+ T cells in COVID-19, the killing capacity of A2/S269+CD8+ T cells was assessed by staining for granzyme A, B, and K, and perforin directly ex vivo. The gene discussed is GZMA; the disease is COVID-19.